FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

← catalyst calendar

NCT07216105 · readout ≤ 529 d

Sponsored by Fate Therapeutics (industry) · FATE — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

113estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-11-04

actual

When the study began enrolling

Primary completion

Jan 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Jan 2030

estimated

The whole study's end, after follow-up

First posted

2025-10-14

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Non-Small Cell Lung Cancer
Colorectal Cancer
Breast Cancer
Ovarian Cancer
Endometrial Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions

Drug: FT836 — also filed as 836
Drug: Paclitaxel — also filed as Taxol
Drug: Cetuximab — also filed as Erbitux
Drug: Trastuzumab — also filed as Herceptin

Primary outcomes

what the primary-completion date above is the date OF

Number of participants with dose limiting toxicities (DLTs)

measured From Day 1 through Day 29 of Cycle 1( each cycle is 56 days)

Severity of DLTs

measured From Day 1 through Day 29 of Cycle 1( each cycle is 56 days)

Permalink · FATE's whole pipeline · Catalyst calendar · Every registered study · What changed